Orthocell Limited (ASX: OCC) - Share Price

Current share price for OCC : $0.740 0.04 (5.13%)⁺

Orthocell Limited (OCC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It operates as a regenerative medicine company engaged in developing products for the repair of bone and soft tissue injuries. The company has appointed a network of specialist distributors in the United States and recorded initial sales. The company's nerve repair product holds approval in Australia, New Zealand and Singapore and is distributed through Device Technologies Group in those markets.

OCC General Information ⁺

ASX Code	OCC
Website	http://www.orthocell.com.au
Industry/Sector	Biotechnology
Market Cap ($M)	201
OCC Share Price	$0.740
Day High	$0.795
Day Low	$0.740
Last Close	$0.780
OCC Share Price Movement	$0.04 ( 5.13% )

Prices as at 16:40, 25 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Orthocell Limited (OCC) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Orthocell Limited (OCC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Orthocell Limited (OCC) price-sensitive announcements

OCC - Q4 FY26 ASX Investor Presentation

Orthocell Limited's Q4 FY26 ASX Investor Presentation highlights a strong quarter with sig

Orthocell Limited (OCC)
14 Jul 2026 | 8:47 AM

OCC - Quarterly Activity Report & Appendix 4C

Orthocell Limited has reported a strong quarterly performance for the period ending 30 Jun

Orthocell Limited (OCC)
13 Jul 2026 | 8:53 AM

OCC - Orthocell Appoints Thailand Distributor for Remplir

Orthocell Limited, a regenerative medicine company, announced the appointment of MediTime

Orthocell Limited (OCC)
3 Jul 2026 | 8:56 AM

OCC - First Sales of Remplir Achieved in US$75m Canadian Market

Orthocell Limited has achieved its first commercial sales of the nerve repair device Rempl

Orthocell Limited (OCC)
30 Apr 2026 | 9:14 AM

Orthocell Limited (OCC) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Orthocell Limited (OCC) ORDINARY FULLY PAID	Health Care	$202	Orthocell Achieves First Remplir Sales in Thailand	21 Sep 2026 8:55AM	$0.690	$0.740	risen by 7.25%
Orthocell Limited (OCC) ORDINARY FULLY PAID	Health Care	$202	Cleansing Notice	11 Sep 2026 3:14PM	$0.710	$0.740	risen by 4.23%
Orthocell Limited (OCC) ORDINARY FULLY PAID	Health Care	$202	Application for quotation of securities - OCC	11 Sep 2026 3:08PM	$0.710	$0.740	risen by 4.23%
Orthocell Limited (OCC) ORDINARY FULLY PAID	Health Care	$202	Date of AGM & Closing Date for Director Nominations	10 Sep 2026 8:30AM	$0.725	$0.740	risen by 2.07%
Orthocell Limited (OCC) ORDINARY FULLY PAID	Health Care	$202	Appendix 4G	31 Aug 2026 12:57PM	$0.730	$0.740	risen by 1.37%
Orthocell Limited (OCC) ORDINARY FULLY PAID	Health Care	$202	Corporate Governance Statement	31 Aug 2026 12:57PM	$0.730	$0.740	risen by 1.37%

OCC Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2028F	C2	-$2.00	-60.00%	0.00%	0.0%
2027F	C2	-$5.00	-2.70%	0.00%	0.0%
2026A	-$13.53	-$5.10	33.90%	0.00%	0.0%

OCC Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
CSL Limited (CSL)	$85,957M	0.7309	-0.4440	0.0545	11.0969	19.9585	18.9263	2.37%	2.32%	2.40%
Mesoblast Limited (MSB)	$2,844M	-0.4380	0.0000	0.0000	0.0000	0.0000	347.6190	0.00%	0.00%	0.00%
Orthocell Limited (OCC)	$212M	0.3385	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$2,862M	-0.3971	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,350M	-1.3893	0.0000	-0.2777	0.0000	174.1150	241.0413	0.00%	0.00%	0.00%

OCC Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	5.85	0.00
Market	0.33	13.80	1.17	0.79
Sector	0.63	30.70	2.72	1.90

OCC Directors

Name	Position	Start Date
Mr Paul Frederick Anderson	Chief Executive Officer, Managing Director	21 Mar 2006
Dr Ravi Thadhani	Lead Independent Director, Non-Executive Director	8 Mar 2023
Mr John Van Der Wielen	Non-Executive Chairman, Non-Executive Director	1 Jun 2023
Professor Fiona Melanie Wood	Non-Executive Director	1 Nov 2023
Mr Michael McNulty	Non-Executive Director	1 Sep 2025

Orthocell Limited (OCC) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
20 Jul 2026	WIELEN, John	Issued	Direct Shares	15,430	$0.756	$11,666.670
17 Jul 2026	WOOD, Fiona	Issued	Indirect Shares	11,573	$0.756	$8,750.000
17 Jul 2026	MCNULTY, Michael	Issued	Indirect Shares	11,573	$0.756	$8,750.000

See all changes in directors' interest & trades for Orthocell Limited (OCC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

OCC Management

Name	Position
Jim Piper	CFO
Peter Webse	Company Secretary
Alex McHenry	COO

OCC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Orthocell Limited (OCC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
0 (0%)	n/a

OCC Calendar of Events

Date	Event
30 August 2027	Report (Annual)
30 August 2027	Report (Prelim)
23 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us